

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C07H 19/16, C07D 487/04, 403/04		A1	(11) International Publication Number: WO 97/03084
			(43) International Publication Date: 30 January 1997 (30.01.97)
(21) International Application Number: PCT/SE96/00911 (22) International Filing Date: 4 July 1996 (04.07.96) (30) Priority Data: 9514074.5      11 July 1995 (11.07.95)      GB 9520311.3      5 October 1995 (05.10.95)      GB 9522837.5      8 November 1995 (08.11.95)      GB (71) Applicant (for all designated States except MG): ASTRA PHARMACEUTICALS LTD. [GB/GB]; Home Park, Kings Langley, Herts. WD4 8DH (GB). (71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): COX, David [GB/GB]; 3 Balvoir Drive, Loughborough, Leics. LE11 25N (GB). IN-GALL, Anthony [GB/GB]; 53 Forest Road, Loughborough, Leics. LE11 3NW (GB). WILLIS, Paul [GB/GB]; 8 Wisley Close, West Bridgford, Nottingham NG2 7NY (GB). (74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).			(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published With international search report.
(54) Title: NEW INHIBITORS OF PLATELET AGGREGATION			
(57) Abstract			
<p>Compounds of formula (I), wherein B is O or CH<sub>2</sub>; X is selected from NR<sup>1</sup>R<sup>2</sup>, SR<sup>1</sup>, and C<sub>1</sub>-C<sub>7</sub> alkyl; Y is selected from SR<sup>1</sup>NR<sup>1</sup>R<sup>2</sup>, and C<sub>1</sub>-C<sub>7</sub> alkyl; R<sup>1</sup> and R<sup>2</sup> are each and independently selected from H, or C<sub>1</sub>-C<sub>7</sub> alkyl optionally substituted upon or within the alkyl chain by one or more of O, S, N or halogen; R<sup>3</sup> and R<sup>4</sup> are both H, or R<sup>3</sup> and R<sup>4</sup> together form a bond; A is COOH, C(O)NH(CH<sub>2</sub>)<sub>p</sub>COOH, C(O)N[(CH<sub>2</sub>)<sub>q</sub>COOH]<sub>2</sub>; C(O)NHCH(COOH)(CH<sub>2</sub>)<sub>r</sub>COOH, or 5-tetrazolyl, wherein p, q and r are each and independently 1, 2, or 3; as well as pharmaceutically acceptable salts and prodrugs thereof, pharmaceutical compositions comprising the novel compounds and use of the compounds in therapy. Also within the scope of the invention are novel intermediates to the novel compounds. The novel compounds are in particular useful in the prevention of platelet aggregation.</p>			
		<p style="text-align: right;">(I)</p>	